Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma 2019 Oct;60(10):2558-2562

Date

03/09/2019

Pubmed ID

30845856

Pubmed Central ID

PMC7176050

DOI

10.1080/10428194.2019.1585836

Scopus ID

2-s2.0-85062788299 (requires institutional sign-in at Scopus site)   12 Citations

Author List

Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F

Authors

Ashley Cunningham MD Associate Professor in the Pathology department at Medical College of Wisconsin
Binod Dhakal MD Associate Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Peiman Hematti MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Biomarkers
Hematopoietic Stem Cell Transplantation
Humans
Immunohistochemistry
Lymphocytes, Tumor-Infiltrating
Multiple Myeloma
Prognosis
Proteolysis
Treatment Outcome
Tumor Microenvironment
Versicans